Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study

Melissa A. Runge-Morris; Merrill S. Kies; Everett Vokes; Richard Blough; Linda Weidner; Richard Knop; Kendrith Rowland

doi:10.1007/BF00170872

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study

Melissa A. Runge-Morris, Merrill S. Kies, Everett Vokes, Richard Blough, Linda Weidner, Richard Knop, Kendrith Rowland

Research output: Contribution to journal › Article › peer-review

Abstract

Eighteen patients entered this study of the efficacy of homoharringtonine (HHT) treatment in advanced squamous cell carcinoma of the head and neck (SCCHN). Seventeen eligible patients received at least one day of the first 5-day cycle of HHT (4.0 mg/m²/day) by continuous IV infusion. Cycles were scheduled to repeat every 28 days. The major severe toxicities encountered were hypotension and myelosuppression. There was one drug-related death. Fourteen patients were evaluable for response, and no patient exhibited an objective response to treatment with HHT.

Original language	English (US)
Pages (from-to)	269-273
Number of pages	5
Journal	Investigational New Drugs
Volume	7
Issue number	2-3
DOIs	https://doi.org/10.1007/BF00170872
State	Published - Jul 1989
Externally published	Yes

Keywords

blood pressure
complete blood count
hematocrit
homoharringtonine
squamous cell carcinoma of the head and neck
white blood cell count

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Online availability

10.1007/BF00170872

Library availability

Discover UIUC Full Text

Cite this

@article{2e421349a17142c5b153cbcc6e701c27,

title = "Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study",

abstract = "Eighteen patients entered this study of the efficacy of homoharringtonine (HHT) treatment in advanced squamous cell carcinoma of the head and neck (SCCHN). Seventeen eligible patients received at least one day of the first 5-day cycle of HHT (4.0 mg/m2/day) by continuous IV infusion. Cycles were scheduled to repeat every 28 days. The major severe toxicities encountered were hypotension and myelosuppression. There was one drug-related death. Fourteen patients were evaluable for response, and no patient exhibited an objective response to treatment with HHT.",

keywords = "blood pressure, complete blood count, hematocrit, homoharringtonine, squamous cell carcinoma of the head and neck, white blood cell count",

author = "Runge-Morris, {Melissa A.} and Kies, {Merrill S.} and Everett Vokes and Richard Blough and Linda Weidner and Richard Knop and Kendrith Rowland",

year = "1989",

month = jul,

doi = "10.1007/BF00170872",

language = "English (US)",

volume = "7",

pages = "269--273",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "2-3",

}

TY - JOUR

T1 - Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck

T2 - A phase II Illinois Cancer Council study

AU - Runge-Morris, Melissa A.

AU - Kies, Merrill S.

AU - Vokes, Everett

AU - Blough, Richard

AU - Weidner, Linda

AU - Knop, Richard

AU - Rowland, Kendrith

PY - 1989/7

Y1 - 1989/7

N2 - Eighteen patients entered this study of the efficacy of homoharringtonine (HHT) treatment in advanced squamous cell carcinoma of the head and neck (SCCHN). Seventeen eligible patients received at least one day of the first 5-day cycle of HHT (4.0 mg/m2/day) by continuous IV infusion. Cycles were scheduled to repeat every 28 days. The major severe toxicities encountered were hypotension and myelosuppression. There was one drug-related death. Fourteen patients were evaluable for response, and no patient exhibited an objective response to treatment with HHT.

AB - Eighteen patients entered this study of the efficacy of homoharringtonine (HHT) treatment in advanced squamous cell carcinoma of the head and neck (SCCHN). Seventeen eligible patients received at least one day of the first 5-day cycle of HHT (4.0 mg/m2/day) by continuous IV infusion. Cycles were scheduled to repeat every 28 days. The major severe toxicities encountered were hypotension and myelosuppression. There was one drug-related death. Fourteen patients were evaluable for response, and no patient exhibited an objective response to treatment with HHT.

KW - blood pressure

KW - complete blood count

KW - hematocrit

KW - homoharringtonine

KW - squamous cell carcinoma of the head and neck

KW - white blood cell count

UR - http://www.scopus.com/inward/record.url?scp=0024322252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024322252&partnerID=8YFLogxK

U2 - 10.1007/BF00170872

DO - 10.1007/BF00170872

M3 - Article

C2 - 2793384

AN - SCOPUS:0024322252

SN - 0167-6997

VL - 7

SP - 269

EP - 273

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2-3

ER -

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: A phase II Illinois Cancer Council study

Abstract

Keywords

ASJC Scopus subject areas

Online availability

Library availability

Related links

Fingerprint

Cite this